# Contact LKN Peptide — Editorial Desk

> Reach the LKN Peptide editorial desk regarding citations, corrections, or research-related correspondence about our Growth Hormone Axis peptide digest.

Correspondence on citations, corrections, and research-related inquiries — the things a reference desk is most useful to hear about.

## Editorial correspondence

LKN Peptide welcomes correspondence on the research record itself: a citation quoted inaccurately, a newly published trial on CJC-1295, ipamorelin, sermorelin, or tesamorelin, a regulatory update that changes an approval or compounding status, or a study that should be added to the [references page](/references). This category of correction — one that improves the accuracy or currency of the digest — is the most useful message this desk receives.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference, ideally with a DOI or PubMed identifier, so a proposed change can be verified against its source before anything is updated.

**Editorial mailbox:** editors@lknpeptide.com

## What this desk cannot do

As a literature digest rather than a clinical service, this desk cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a cited finding applies to a specific person's situation, or help locate, source, or evaluate any supplier. Sermorelin, tesamorelin, and the CJC-1295/ipamorelin combination each carry different regulatory statuses — from an approved prescription indication to unregulated research-chemical status — and none of that status information is a substitute for consulting a licensed clinician. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.

---

LKN Peptide pairs every enthusiastic finding about the growth-hormone axis with its citation and its caveat in the same breath — a research digest, not a clinic and not a supplier.